Semax is a synthetic fragment of ACTH developed in Russia and registered as a medicine there. Its neurotrophic findings come from rat ischemia models, its clinical data from Russian stroke patients, and no Western trial in healthy people exists.
Peptide Research
Published by Astra, which offers some of the treatments discussed. Educational, not medical advice.
Semax is a short synthetic peptide based on ACTH(4-10), a seven-amino-acid stretch of adrenocorticotropic hormone, with a proline-glycine-proline tail attached to slow enzymatic degradation. In the literature it is often written as the ACTH(4-7)PGP peptide.5
The design logic is worth understanding because it explains what Semax is and is not. ACTH is best known as the pituitary hormone that tells the adrenal glands to release cortisol. That activity lives in a different part of the molecule. The 4-10 fragment was pursued because it appeared to carry behavioural and neurotrophic effects in the brain without triggering the adrenal axis. Semax is therefore not a steroid and does not raise cortisol; it is a fragment selected specifically to avoid that.
It was developed in Russia and is administered intranasally, which is unusual and deliberate. A peptide of this size does not cross the blood-brain barrier well from the bloodstream, and the intranasal route is intended to give better access to the central nervous system. How much of an intranasal dose actually reaches human brain tissue is not well characterised in published Western pharmacokinetic work.
Semax occupies a specific and rarely-acknowledged position: it is a real registered pharmaceutical, just in one country, with a research literature written largely in one language by researchers within a single national scientific tradition. That is not a reason to dismiss it. It is a reason to be precise about what has been demonstrated and by whom.
The mechanistic claim behind Semax is that it increases brain-derived neurotrophic factor and related neurotrophins. BDNF supports neuron survival, synaptic plasticity, and the structural changes underlying learning, so a molecule that raises it is an appealing story for anyone selling cognitive enhancement.
The primary evidence is rodent. Semax and Pro-Gly-Pro were shown to activate transcription of neurotrophins and their receptor genes after cerebral ischemia in rats.3 A genome-wide transcriptional analysis in a rat model of focal brain ischemia found Semax affected expression of genes related to the immune and vascular systems.4 A brain protein expression profile study in a rat ischemia-reperfusion model reported a protective effect of the ACTH(4-7)PGP peptide.5
A separate rat study examined behavioural and neurochemical alterations following early-life fluvoxamine exposure and reported that Semax attenuated them.2 Different model, same species, and again a damaged or perturbed nervous system rather than a healthy one.
Notice the pattern across all four. Every one of these studies involves a rat and, in three of the four, an injured brain. Ischemia work asks whether a compound protects tissue that is dying from interrupted blood flow. Neuroprotection in that setting is a real and valuable property, and it says close to nothing about whether the same compound sharpens attention or memory in an intact, well-perfused human brain. A drug that limits damage in a crisis and a drug that improves function at baseline are two different pharmacological categories that happen to share a marketing vocabulary.
The human data is a Russian clinical study of Semax efficacy in patients at different stages of ischemic stroke.1 This is the study underlying essentially every statement that Semax 'works in humans.'
Its population is stroke patients. Its setting is Russian clinical practice, where Semax is a registered medicine and its use in stroke is an accepted indication rather than an experimental question. Its publication is in a Russian-language neurology and psychiatry journal.
None of that makes it a bad study. It does mean the result generalises only to what it studied. The finding, taken at face value, is that Semax was efficacious in patients recovering from ischemic stroke. It is not a finding about memory in healthy adults, focus during work, mood in people without neurological injury, or protection against future cognitive decline in anyone. Those claims have not been tested.
There is also no independent Western replication. No large randomised trial run outside Russia has evaluated Semax for any indication. This is the same structural weakness that appears throughout investigational peptide literature: a body of work produced within one research tradition, unexamined by outside groups working under different incentives and different methodological conventions. Independent replication is precisely the step that catches errors an insider group cannot see in itself, and for Semax that step has not happened.
Say this part plainly, because Semax marketing routinely obscures it. Semax is not a legal medicine in the United States. Its registration in Russia confers no status with the FDA and does not make it available through any US prescription pathway.
Approval is not a portable global judgment. Each regulator evaluates a dossier against its own evidentiary standard, and the fact that one national authority registered a drug decades ago under a different regulatory framework tells you very little about whether it would clear a modern FDA review. Drugs approved in one country and rejected or never submitted in another are common, and the reasons range from insufficient trial data to safety signals to a sponsor simply never applying.
The practical consequence is that Semax sold to US buyers arrives through the research-chemical channel or through personal importation, not through a pharmacy. Neither route involves a licensed pharmacist verifying the preparation or a prescriber evaluating whether it is appropriate. Nasal formulations still require sterile preparation and correct concentration, and neither is verified in that supply chain.
Semax is not an FDA-approved drug. It is also not currently legal to compound in the United States, so a licensed US compounding pharmacy cannot prepare it against a prescription.
The FDA's Pharmacy Compounding Advisory Committee reviewed several of these peptides in July 2026. PCAC is advisory and no rule has been issued. Any source presenting a decision, a timeline, or an availability date for Semax is describing something that has not been published.
This is why Semax appears here as an educational entry rather than as a product. Astra does not sell it, cannot prescribe it, and will not publish a dose for it.
Two questions handle nearly every Semax claim you will encounter. Was this a rat or a person? And if a person, were they recovering from a stroke or were they healthy?
Applied to the actual literature: neurotrophin and BDNF gene activation, rats with induced ischemia.3 Immune and vascular gene expression changes, rats with focal ischemia.4 Protein-level neuroprotection, rats with ischemia-reperfusion injury.5 Behavioural normalisation after early-life drug exposure, rats.2 Clinical efficacy, human stroke patients in Russia.1
There is no entry in that list for healthy human cognition, which is the use case Semax is overwhelmingly sold for. The gap is not subtle and it is not a matter of interpretation. It is a category of study that has not been done.
Semax may well be a useful neuroprotective agent; the Russian clinical tradition has treated it as one for years and the rodent mechanistic work is coherent. What it is not is a validated cognitive enhancer for healthy adults, and no amount of citation stacking from ischemia models converts it into one.
Semax is studied as a stroke drug and sold as a study aid. Those are different populations, different brains, and different questions.
Astra Editorial, reviewing the Semax literature
No. Semax is registered as a medicine in Russia and is not a legal medicine in the United States. It is not FDA-approved and is not currently available for compounding here.
The neurotrophin and BDNF findings come from rat models of cerebral ischemia. No published human study has demonstrated that Semax raises BDNF in healthy people.
No Western trial has tested Semax for cognitive enhancement in healthy adults. The human clinical evidence comes from Russian research in ischemic stroke patients.
Semax is not sold at Astra. It is not FDA-approved, it is not a legal medicine in the United States, and it is not currently available for compounding here, so there is no legitimate prescription pathway to it today. Keep reading in the Astra Learn library, and we will publish an update if Western trial data or the regulatory picture changes.
This guide is educational and is not medical advice. Compounded medications are not FDA-approved. Speak with a licensed physician about your own care.